Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04063072
Other study ID # ERAS-Gyneco-Piemonte
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2019
Est. completion date October 31, 2021

Study information

Verified date June 2021
Source Ospedale Regina Montis Regalis
Contact Andrea Puppo, MD
Phone 0039 0174677
Email andrea.puppo@aslcn1.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study assesses the impact on quality of care of implementing the ERAS (Enhanced Recovery After Surgery) protocol for hysterectomy of benign or malignant tumors of the uterus in the network of public hospitals in the Regione Piemonte (North-West Italy). Every hospital is a cluster entering the study treating patients according to its current clinical practice. On the basis of a randomized order, each hospital switches from current clinical practice to the adoption of the ERAS protocol.


Description:

ERAS (Enhanced Recovery After Surgery) protocol is a multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery. Even if efficacy and safety of ERAS protocol in gynaecological surgery is well-established in the literature, its implementation is limited to few selected centres in Piemonte. The aim of the study is to extend the implementation of the ERAS protocol to whole regional network of hospitals. Specific objectives are to estimate its impact on different dimensions of quality of care, including length of stay, complications and patient satisfaction, and to identify possible barriers or facilitating factors.


Recruitment information / eligibility

Status Recruiting
Enrollment 1800
Est. completion date October 31, 2021
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - All the hospital wards within the Piemonte Region performing hysterectomy. - All the patients receiving an elective hysterectomy for benign or malignant tumors of the uterus. Exclusion Criteria: - Hospital wards performing less than 20 expected cases per year - Emergency hysterectomy - Hysterectomy for pelvic floor disorders - High severity cases not allowing ERAS protocol implementation (i.e. American Society of Anesthesiologists score: ASA V).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ERAS protocol
In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.

Locations

Country Name City State
Italy Ospedale Regina Montis Regalis Mondovì

Sponsors (5)

Lead Sponsor Collaborator
Ospedale Regina Montis Regalis Azienda Ospedaliera Città della Salute e della Scienza di Torino, Martini Hospital, Turin, Italy, Ministry of Health, Italy, Regione Piemonte

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, Taylor JS, Iniesta M, Lasala J, Mena G, Scott M, Gillis C, Elias K, Wijk L, Huang J, Nygren J, Ljungqvist O, Ramirez PT, Dowdy SC. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update. Int J Gynecol Cancer. 2019 May;29(4):651-668. doi: 10.1136/ijgc-2019-000356. Epub 2019 Mar 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Length of stay Mean length of stay calculated as difference between date of discharge and date of admission of the hospitalization for surgery, excluding length of stay >12 days (98th percentile of the expected distribution). 12 days after admission
Secondary Length of stay >12 days Rate of patients with a length of stay >12 days 30 days after admission
Secondary Recovery after surgery Score of quality of recovery at 24 hours after surgery, assessed with the questionnaire Quality of Recovery (QoR-15), a 15-items instrument, with responses recorded on a 11-point Likert-type scale form 0 (worst scenario) to 10 (best scenario) and an overall score ranging from 0 (poor recovery) to 150 (excellent recovery).
A visual analogue scale (VAS), ranging from 0 (worst imaginable health state) to 10 (worst imaginable health state) is also supplied as summary evaluation.
24 hours after surgery
Secondary Complications Rate of surgical and medical complication after surgery For surgical complications: Comprehensive Complication Index 30 days after discharge
Secondary Transfer to intensive care unit Rate of transfers to intensive care unit after surgery 30 days after surgery
Secondary Emergency visits after discharge Rate of emergency visit in the first month after discharge 30 days after discharge
Secondary Hospital admissions after discharge Rate of new admissions in the first month after discharge 30 days after discharge
Secondary Reintervention Rate of reintervention in the first month after surgery, excluding planned interventions 30 days after surgery
Secondary Patients' satisfaction Score of patients' satisfaction measured 2 weeks after discharge, assessed with the questionnaire Surgical Satisfaction Questionnaire (SSQ8) supplied by telephone. SSQ8 is a 8-items instrument, with responses recorded on a 5-point Likert-type scale from 0 (worst scenario) to 4 (best scenario) and an overall score ranging from 0 (very unsatisfied) to 32 (very satisfied). 15 days after discharge
Secondary Healthcare costs Mean healthcare costs from pre admission visit to 30 days after discharge 30 days after discharge
See also
  Status Clinical Trial Phase
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Terminated NCT00669422 - ChemoFx® PRO - A Post-Market Data Collection Study N/A
Recruiting NCT01564264 - Sentinel Node Biopsy in Endometrial Cancer N/A
Completed NCT00231855 - Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers Phase 2
Completed NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial N/A
Completed NCT04351139 - Impact of the COVID-19 Pandemic in Gynecological Oncology
Completed NCT05004623 - Early Feasibility Study of the "Easy Light" Fluorecence Imaging System N/A
Completed NCT00112307 - Magnetic Resonance Imaging Guided Gynecologic Brachytherapy N/A
Completed NCT02454036 - Biobehavioral Intervention in Gynecologic Oncology Patients Phase 2
Completed NCT00188578 - Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2) Phase 1/Phase 2
Active, not recruiting NCT03951415 - Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer Phase 2
Completed NCT01654458 - A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer N/A
Completed NCT00190918 - A Trial for Patients With Gestational Trophoblastic Disease Phase 2
Completed NCT00050440 - Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma Phase 2
Completed NCT00250783 - Pre-Clinical Models in Gynecological Tumors A Tissue Repository
Recruiting NCT03624712 - Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms
Completed NCT00628901 - A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Phase 4
Completed NCT00090389 - Acupuncture for Women's Health Conditions Phase 1